Hørsholm, Denmark, 12 December 2023 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") will provide a webcast update on the recently announced Nipah virus vaccine project on 14 December 2023.

By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company's website.

14 December 2023 | Update on EU-Funded Nipah Virus Vaccine Project
10:00 CET | Virtual
ExpreS2ion Biotechnologies recently announced the award of a grant that amounts to EUR 8m (approx. SEK 90m) for the VICI-Disease consortium. 53% of the amount is a direct contribution to ExpreS2ion's part of the project costs. The development project aims to obtain clinical proof-of-concept of a Nipah virus (NiV) vaccine candidate.

CEO Bent Frandsen will dig deeper into the news in a live virtual event hosted by H.C. Andersen Capital on the Inderes platform. You can ask questions before or during the live event through the registration link here: https://www.inderes.dk/videos/expres2ion-biotechnologies-update-on-eu-funded-nipah-virus-vaccine-project

To pose questions ahead of time to be addressed at the webcast, please email ExpreS2ion at investor@expres2ionbio.com.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB

For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com 

About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2(TM), for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2(TM), includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.

https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-to-present-new-nipah-virus-vaccine-project-in-upcoming-webcast,c3891260

https://mb.cision.com/Main/14402/3891260/2484471.pdf

(c) 2023 Cision. All rights reserved., source Press Releases - English